NRX Pharmaceuticals, Inc. - FORM 10-K - EX-32.1 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - March 23, 2018

Attached files

file filename
EX-31.1 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - NRX Pharmaceuticals, Inc.brpa_ex311.htm
EX-32.2 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - NRX Pharmaceuticals, Inc.brpa_ex322.htm
EX-31.2 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - NRX Pharmaceuticals, Inc.bpra_ex312.htm
10-K - ANNUAL REPORT - NRX Pharmaceuticals, Inc.brpa_10k.htm
 
 Exhibit 32.1
 
CERTIFICATION PURSUANT
TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the accompanying Annual Report on Form 10-K of Big Rock Partners Acquisition Corp. (the "Company") for the year ended December 31, 2017, as filed with the U.S. Securities and Exchange Commission (the “Report”), the undersigned hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge and belief, that:
 
1.
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
 
2.
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
 
 
 
 
March 23, 2018
By:  
/s/ Richard Ackerman
 
 
 
Richard Ackerman
 
 
 
Chairman, President and Chief Executive Officer
(principal executive officer)
 
 
 
 
 
 
 
 

NRX Pharmaceuticals, Inc. Reports